Precision BioSciences (NASDAQ:DTIL) Now Covered by Analysts at Guggenheim

Guggenheim began coverage on shares of Precision BioSciences (NASDAQ:DTIL) in a report published on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $19.00 price objective on the stock.

Separately, HC Wainwright reissued a buy rating and set a $60.00 price objective on shares of Precision BioSciences in a report on Wednesday, April 17th.

Precision BioSciences Price Performance

Shares of NASDAQ:DTIL opened at $10.41 on Tuesday. The company has a market capitalization of $72.00 million, a P/E ratio of -0.65 and a beta of 1.53. Precision BioSciences has a 1 year low of $8.25 and a 1 year high of $27.02. The business’s 50 day simple moving average is $12.67 and its 200 day simple moving average is $11.79.

Precision BioSciences (NASDAQ:DTIL) last issued its earnings results on Wednesday, March 27th. The company reported ($3.35) earnings per share for the quarter, missing analysts’ consensus estimates of $3.00 by ($6.35). The business had revenue of $7.04 million during the quarter, compared to analyst estimates of $28.50 million. Precision BioSciences had a negative net margin of 125.84% and a negative return on equity of 204.66%. On average, sell-side analysts anticipate that Precision BioSciences will post -3.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DTIL. Curi Wealth Management LLC raised its position in Precision BioSciences by 42.0% during the 3rd quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock worth $116,000 after purchasing an additional 100,530 shares during the last quarter. Tejara Capital Ltd raised its position in shares of Precision BioSciences by 100.7% in the 3rd quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock worth $136,000 after acquiring an additional 200,000 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in shares of Precision BioSciences by 8.3% in the 3rd quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock worth $1,073,000 after acquiring an additional 242,425 shares in the last quarter. 37.99% of the stock is owned by institutional investors.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.